When the Hospital Pharmacy Has No Chemotherapy Drug, Try Calling the Manufacturer
A widely shared Weibo post described how a family that couldn't find an originator chemotherapy drug anywhere — hospital, pharmacy, even Hong Kong — solved the problem with one phone call to the manufacturer's patient hotline, turning the experience of drug shortages into a national conversation.
The post that carried this story needed no photographs. A security engineer known on Weibo as tombkeeper (Tom Li, in real life one of China's best-known cybersecurity researchers) wrote on Tuesday evening that a friend's family member had fallen ill and needed an originator chemotherapy drug — the brand-name version made by the international pharmaceutical company that developed it. The local hospital pharmacy did not stock it. Even paying out of pocket, without insurance, she could not get it prescribed. Online pharmacies barely had it, and marked it up steeply. She researched buying it in Hong Kong, until she learned that requires a prescription from a Hong Kong doctor.
"I gave her the pharmaceutical company's China hotline — the 400 number — and told her to just call," Li wrote. "Today she told me the problem was fully solved." The company delivered the drug directly to the hospital, at a normal price. Her verdict, as he relayed it: "I tried countless workarounds, and it never occurred to me to contact the manufacturer directly."
The post drew nearly a thousand reposts within a day and pushed the topic onto Weibo's hot list, because almost everyone in China has a version of this story. Comments filled with accounts of cancer drugs, rare-disease treatments and children's medications that hospitals stopped stocking or never carried, and families reduced to asking strangers where to turn.
The shortage has a structural backdrop. Since 2019 China's centralized procurement program has swapped brand-name drugs for cheap generics across thousands of hospital formularies, and originator medicines that lose the tender tend to drift out of hospital pharmacies entirely — officially still on sale, practically hard to find. The state has built a shortage-drug supply system that encourages exactly the channel Li's friend stumbled into: direct contact between patients, manufacturers and medical institutions through a maker's patient-support line. Commentators on the topic this week stressed that it is a legal, sanctioned route — and, as one poster cautioned, one that still requires a regular doctor's prescription behind it.
The resonance also carried a film title. "It reminds me of 'Dying to Survive,'" one commenter wrote, invoking the 2018 blockbuster about cancer patients smuggling cheaper generic drugs from India — the movie that turned drug affordability into national policy talk and pushed Beijing to bring dozens of cancer medicines into insurance coverage. Six years on, the argument has shifted: the drugs exist, and often the insurance covers part of the cost, but the last mile between the pharmacy and the patient is where the system frays.
Li's own closing note was less about medicine than about how things work in China: when the internet gives you only "all kinds of dubious second-hand information," he wrote, walk into the relevant office and ask the staff directly — it took him minutes. For the families following his advice with a chemotherapy drug at stake, the lesson is narrower and harder: the direct route exists, it is free to try, and it is known mostly to the people who least expect it to work.